[Effects of irbesartan on renal advanced glycation end products and their receptor in rats with early diabetic nephropathy]. 2009

Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
Nephropathy Center of Integrated TCM and Western Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. lymlhbcj@hotmail.com

OBJECTIVE To investigate the effect of irbesartan on the renal expressions of advanced glycation end products (AGEs) and their receptor (RAGEs) in rats with early diabetic nephropathy (DN) and the renoprotection mechanism of irbesartan. METHODS Rat DN models established by a single injection of streptozotocin were randomly divided into the model group and irbesartan treatment group. With normal rats as the control, all the rats received daily gavage for 8 weeks. The 24-h urinary protein excretion and contents of AGEs in the serum and kidney tissues were measured. The expressions of RAGEs and RAGEs protein and mRNA in the kidney tissues were detected by immunohistochemistry and reverse transcription-polymerase chain reaction, respectively. The pathological changes of the kidney were also assessed microscopically. RESULTS Irbesartan significantly reduced the 24-h urinary protein excretion and the contents of AGEs in the serum and kidney tissues of DN rats, resulting also in decreased expressions of RAGEs and RAGEs protein and mRNA levels in the kidney. The treatment obviously alleviated the pathological changes in the kidney of the DN rats. CONCLUSIONS Irbesartan offers renoprotection against DN possibly by reducing the serum and renal contents of AGEs and inhibiting the renal mRNA expressions of RAGEs and RAGEs.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D000067759 Receptor for Advanced Glycation End Products A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. Advanced Glycation End Product Receptor,Advanced Glycation End Product Receptors,Receptor For Advanced Glycation End Product,Receptor for Advanced Glycation Endproduct,AGE Receptor,AGER Protein,Amphoterin Receptor,RAGE (Receptor for Advanced Glycation End Products),Receptor for Advanced Glycation End Products (RAGE),Receptor for Advanced Glycation Endproducts,Receptor, Amphoterin
D000077405 Irbesartan A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease. 2-N-Butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one,Aprovel,Avapro,BMS 186295,BMS-186295,Karvea,SR 47436,SR-47436,SR47436
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl

Related Publications

Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 2005, American journal of therapeutics,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 2001, Contributions to nephrology,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
September 2000, Journal of the American Society of Nephrology : JASN,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
August 2003, Journal of the American Society of Nephrology : JASN,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
October 2013, Diabetes care,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 2010, Oxidative medicine and cellular longevity,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
January 2001, Contributions to nephrology,
Hai-bo Long, and Hong-xin Niu, and Xiao-yun Li, and Wei-dong Zhou, and Jing-hua He, and Juan Zhong, and Lian-bo Wei
March 2014, Journal of physiology and biochemistry,
Copied contents to your clipboard!